Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?
Sarepta and Amarin: How These Biotech Stocks Stack Up(Continued from Prior Part)Revenue guidance In its fourth-quarter earnings conference call, Sarepta Therapeutics (SRPT) guided for fiscal 2019 revenues in the range of $365 million to $375 million,